Video Experimental Relacionado
Updated: Jul 16, 2026
11:13
Porcine Model of Infrarenal Abdominal Aortic Aneurysm
Published on: November 21, 2019
Prolongación del tiempo de sangrado inducida por la aspirina y pérdida de sangre perioperatoria
JAMA
|May 8, 1981
Resumen
La terapia con aspirina para pacientes con reemplazo de cadera prolongó los tiempos de sangrado, pero no aumentó la pérdida de sangre perioperatoria. Las dosis más altas de aspirina no mostraron un acortamiento paradójico de los tiempos de sangrado.
Área de la Ciencia:
- Cirugía Ortopédica Cirugía ortopédica.
- Farmacología Farmacología.
Sus antecedentes:
- El reemplazo total de cadera es un procedimiento quirúrgico común.
- La anticoagulación eficaz es crucial para prevenir las complicaciones perioperatorias.
Objetivo del estudio:
- Para investigar el efecto de diferentes dosis de aspirina en los tiempos de sangrado y pérdida de sangre perioperatoria en pacientes sometidos a reemplazo total de cadera.
Principales métodos:
- 129 pacientes sometidos a un reemplazo total de cadera fueron asignados al azar para recibir 1,2 g/día o 3,6 g/día de aspirina.
- Los tiempos de sangrado se midieron al inicio, 2 horas después de la dosis y después de 3-5 días de terapia.
- La pérdida de sangre perioperatoria se comparó con los controles históricos.
Principales resultados:
- El tratamiento con aspirina prolongó significativamente los tiempos de sangrado en comparación con el valor basal en ambos niveles de dosis.
- No se observó un acortamiento paradójico del tiempo de sangrado incluso con la dosis más alta (3,6 g/día).
- La pérdida de sangre perioperatoria no aumentó significativamente en la mayoría de los subconjuntos de pacientes tratados con aspirina en comparación con los controles históricos.
Conclusiones:
- La aspirina prolonga el tiempo de sangrado de una manera dependiente de la dosis en pacientes sometidos a reemplazo total de cadera.
- La prolongación observada del tiempo de sangrado no parece traducirse en un aumento de la pérdida de sangre perioperatoria.
- La aspirina se puede utilizar con seguridad para la tromboprofilaxis en el reemplazo total de cadera sin un aumento significativo en el sangrado quirúrgico.
Videos de Conceptos Relacionados
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...